Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Elevance Health Gains as Investors Revisit Guidance and Shift Toward Defensive Healthcare

None

Elevance Health (ELV) is up 3.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely drivers appear to be a combination of company-specific guidance support and a broader move into defensive healthcare shares. Elevance recently reaffirmed its 2026 earnings outlook and medical cost ratio expectations, and that steadier outlook may have looked more attractive as investors rotated away from riskier parts of the market.

Details:

  • On November 10, Elevance filed an 8-K stating that management planned to reaffirm full-year 2026 shareholders’ earnings guidance of at least $22.00 per diluted share and adjusted shareholders’ earnings of at least $29.00 per diluted share.
  • The same filing reaffirmed full-year 2026 benefit expense ratio guidance of 90.2%, plus or minus 50 basis points, which can signal stability around medical cost expectations.
  • In its third-quarter earnings release on October 21, the company raised its 2026 diluted EPS guidance to at least $22.00 and adjusted diluted EPS guidance to at least $29.00, citing continued operating momentum.
  • Healthcare shares were also broadly stronger at the November 16 open, which suggests part of ELV’s move could be tied to sector rotation into more defensive names rather than a single new company announcement today.
  • Sources:

    SEC, Elevance Health, 24/7 Wall St.

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $ELV Insider Trading Activity

    ELV Insider Trades

    $ELV insiders have traded $ELV stock on the open market 20 times in the past 6 months. Of those trades, 3 have been purchases and 17 have been sales.

    Here’s a breakdown of recent trading of $ELV stock by insiders over the last 6 months:

    • MARK KAYE (EVP & CFO) has made 0 purchases and 13 sales selling 10,584 shares for an estimated $4,658,357.
    • GAIL BOUDREAUX (President and CEO) has made 2 purchases buying 2,725 shares for an estimated $1,002,230 and 0 sales.
    • RONALD W PENCZEK (CAO & Controller) has made 0 purchases and 2 sales selling 1,900 shares for an estimated $765,958.
    • RATNAKAR LAVU (EVP & Chief Digital Info Ofr) sold 1,300 shares for an estimated $572,000
    • RAMIRO G PERU purchased 1,000 shares for an estimated $366,050
    • ROBERT L JR DIXON sold 151 shares for an estimated $60,667

    To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

    $ELV Hedge Fund Activity

    We have seen 816 institutional investors add shares of $ELV stock to their portfolio, and 760 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

    $ELV Government Contracts

    We have seen $281,879,931 of award payments to $ELV over the last year.

    Here are some of the awards which we have have seen pay out the most over the last year:

    To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

    $ELV Analyst Ratings

    Wall Street analysts have issued reports on $ELV in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

    Here are some recent analyst ratings:

    • Wells Fargo issued a "Overweight" rating on 10/27/2026
    • TD Cowen issued a "Buy" rating on 10/23/2026
    • UBS issued a "Buy" rating on 10/22/2026
    • Guggenheim issued a "Buy" rating on 10/22/2026
    • Barclays issued a "Overweight" rating on 10/22/2026
    • Bernstein issued a "Outperform" rating on 07/17/2026
    • Truist Securities issued a "Buy" rating on 07/14/2026

    To track analyst ratings and price targets for $ELV, check out Quiver Quantitative's $ELV forecast page.

    $ELV Price Targets

    Multiple analysts have issued price targets for $ELV recently. We have seen 15 analysts offer price targets for $ELV in the last 6 months, with a median target of $472.0.

    Here are some recent targets:

    • Stephen Baxter from Wells Fargo set a target price of $492.0 on 10/27/2026
    • Ryan Langston from TD Cowen set a target price of $495.0 on 10/23/2026
    • A.J. Rice from UBS set a target price of $523.0 on 10/22/2026
    • Jason Cassorla from Guggenheim set a target price of $485.0 on 10/22/2026
    • Erin Wright from Morgan Stanley set a target price of $449.0 on 10/22/2026
    • Ben Hendrix from RBC Capital set a target price of $455.0 on 10/22/2026
    • Andrew Mok from Barclays set a target price of $472.0 on 10/22/2026

    This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

    Add Quiver Quantitative to your preferred sources on Google Google News Logo

    Suggested Articles